Your email has been successfully added to our mailing list.

×
0 0.00010027073097368 0.00010027073097368 -0.00010027073097368 -0.000300812192920898 -0.00010027073097368 0 -0.00010027073097368
Stock impact report

Eli Lilly Had Good Reason To Spend $1.6B On Armo [Seeking Alpha]

ARMO BIOSCIENCES (ARMO) 
US:NASDAQ Investor Relations: armobio.com
Company Research Source: Seeking Alpha
Eli Lilly Had Good Reason To Spend $1.6B On ArmoSummaryLast week Eli Lilly (LLY) spent $1.6 billion on to acquire Armo BioSciences (ARMO) at a 66% premium to its previous closing price.While Armo does have a phase 3 asset, pegilodecakin, in its pipeline, I believe a more valuable asset is in Phase I, a combination approach with Merck's (MRK) Keytruda.The successful combination of pegilodecakin with Keytruda could help vastly expand an already blockbuster market for the drug by turning non-responders into responders. Show less Read more
Impact Snapshot
Event Time:
ARMO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for ARMO alerts
Opt-in for
ARMO alerts

from News Quantified
Opt-in for
ARMO alerts

from News Quantified